Hillsdale Investment Management Inc. Sells 29,260 Shares of Merck & Co., Inc. $MRK

Hillsdale Investment Management Inc. trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 50.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 29,131 shares of the company’s stock after selling 29,260 shares during the period. Hillsdale Investment Management Inc.’s holdings in Merck & Co., Inc. were worth $3,066,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. DLD Asset Management LP raised its holdings in shares of Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the period. Jennison Associates LLC purchased a new stake in shares of Merck & Co., Inc. in the fourth quarter worth approximately $585,192,000. Invesco Ltd. raised its holdings in shares of Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after buying an additional 2,821,766 shares during the period. Ameriprise Financial Inc. raised its holdings in shares of Merck & Co., Inc. by 20.7% in the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after buying an additional 2,735,459 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company’s stock worth $26,770,014,000 after buying an additional 2,185,853 shares during the period. 76.07% of the stock is owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA granted Breakthrough Therapy designation to calderasib (MK-1084) with Keytruda in a lung cancer indication, a sign the program may move faster and expand Merck’s oncology growth prospects. Article Title
• Positive Sentiment: Analyst coverage and recent articles highlighted Merck’s newer drugs, pipeline assets, and M&A options as potential offsets to looming Keytruda patent expiration, reinforcing the bull case for long-term growth. Article Title
• Positive Sentiment: Merck has also been drawing investor attention as a trending stock and has outperformed the S&P 500 over the past year, suggesting market confidence remains relatively strong. Article Title
• Neutral Sentiment: Merck will participate in the Jefferies Global Healthcare Conference, which could provide an update on strategy but is not itself a major business catalyst. Article Title
• Neutral Sentiment: Shareholders backed board nominees, pay, and auditor ratification at the annual meeting, which reduces governance uncertainty but is unlikely to move the stock much. Article Title
• Negative Sentiment: The main longer-term concern remains Keytruda’s eventual loss of exclusivity, which could pressure Merck’s biggest revenue driver if replacement products do not scale quickly enough. Article Title

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $118.49 on Monday. The stock has a 50-day simple moving average of $116.39 and a two-hundred day simple moving average of $111.63. The firm has a market capitalization of $292.66 billion, a P/E ratio of 33.38, a PEG ratio of 2.67 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $75.40 and a fifty-two week high of $125.14. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business posted $2.22 EPS. The company’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Wall Street Analyst Weigh In

MRK has been the topic of several recent analyst reports. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Cantor Fitzgerald lifted their price target on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Wells Fargo & Company lowered their price objective on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. Finally, UBS Group raised their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.